Hard question as only case trials have been done. It is hit and miss for many people. From my research I know that the drugs shown below have helped with varying efficacy, this should be taken with a grain of salt as these studies had no control group so placebo affect is possible (1). This goes for depression as well (2)
Also, as mentioned in many articles that 'treated' with benzodiazapines could be inaccurate as it is possible their anxiety reduced causing perceived improvement of HPPD symptoms. (1)
I would also suggest, that use of antidepressants and anxiolytics drugs are used when you are diagnosed with these disorders in conjunction with HPPD.
Additionally, if pharmacological intervention is not your preference, mentioned in this article was the utilization of psychotherapy, behaviour modification, and even sunglasses. (1)
Drug name. (1) Improved/Total (1)
Clonidine. 9/11
Olanzipine + Fluoxetine. 1/1
Haloperidol. 7/8
Diphenylhydantion. 2/2
Trifluoperazine. 1/1
Barbiturates. 1/1
Benzodiazapines. 8/9
Benzodiazapines. 2/2
Carbamazapine. 1/1
Sertraline. 1/1
Naltrexone. 1/1
The most common HPPD benzodiazepine I have seen used in treatment is clonazepam.
Reboxetine was used in a clinical case study to treat HPPD with depressive features (2)
In addition to these drugs SSRIs, anticonvulsants and neuroleptics have shown efficacy. (1)
Paroxetine, and antidepressant caused an individual to report more extreme and reoccurring HPPD symptoms (2)
With mentioning what has worked I should point out that not all antipsychotics work e.g. risperidone and some SSRI are not advised, these drugs have been shown to WORSEN HPPD symptoms. (1)
(1) J, Halpern & H, Pope (2003) 'Hallucinogern persisting perception disorder: what we know after 50 years?', Drug and Alcohol Dependence, No. 69, Pp. 109-119.
(2) A. Lerner, E. Shufman, A. Kodesh, G. Kretzmer & M. Sigel (2002) LSD-induced hallucinogen persisting perception disorder with depressive features treated with reboxetine: case report, The Isreal Journal of Psychiatry and Related Sciences, No. 39, Iss. 2, Pp. 100-103.